Drug recall · June 26, 2024
Cefixime for Oral Suspension USP 200 mg/5 mL recall
Why: Failed Content Uniformity Specifications
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Cefixime for Oral Suspension USP 200 mg/5 mL (50 mL Pack size), Powder for oral suspension, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore Maryland, Manufactured by: Lupin Limited, Mandideep, India NDC 68180-407-03
- Lots / codes
Lot F201519, Expiry: November 2024
- Quantity
- 3,552 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Nationwide in the US
- Initiated
- May 30, 2024 · Voluntary: Firm initiated
- Classified
- June 18, 2024
- Reported
- June 26, 2024
- Ended
- April 29, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Cefixime
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.